zoliflodacin , DNA gyrase inhibitor, CAS No.1620458-09-4, DNA gyrase inhibitor

Item Number
Z614982
Grouped product items
SKUSizeAvailabilityPrice Qty
Z614982-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$99.90
Z614982-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$259.90
Z614982-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
Z614982-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$679.90
Z614982-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$929.90
Z614982-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,299.90
View related series
DNA gyrase Inhibitor

Basic Description

SynonymsAC-35757 | FWL2263R77 | EXT-0914 | (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione | UNII-F
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionDNA gyrase inhibitor
Product Description

Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.

Product Properties

ALogP1.3

Associated Targets(Human)

HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

gyrA DNA gyrase subunit A (187 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Staphylococcus aureus (210822 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Escherichia coli (133304 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mycobacterium tuberculosis (203094 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L5178Y (1809 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
gyrB DNA gyrase (2092 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
INCHI InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
InChi Key ZSWMIFNWDQEXDT-ZESJGQACSA-N
Canonical SMILES CC1CN2C(C(O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6C(COC6=O)C)C(=O)NC(=O)NC3=O
Isomeric SMILES C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
Alternate CAS 1620458-09-4
PubChem CID 76685216
MeSH Entry Terms (2R,4S,4AS)-11-fluoro-2,4-dimethyl-8-((4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'H,6H-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'H,3'H)-trione;AZD-0914;AZD0914;ETX-0914;ETX0914;zoliflodacin
Molecular Weight 487.44

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

11 results found

Lot NumberCertificate TypeDateItem
J2431567Certificate of AnalysisSep 13, 2024 Z614982
J2431574Certificate of AnalysisSep 13, 2024 Z614982
J2411571Certificate of AnalysisSep 13, 2024 Z614982
J2431562Certificate of AnalysisSep 13, 2024 Z614982
J2431563Certificate of AnalysisSep 13, 2024 Z614982
J2431564Certificate of AnalysisSep 13, 2024 Z614982
J2431565Certificate of AnalysisSep 13, 2024 Z614982
J2431566Certificate of AnalysisSep 13, 2024 Z614982
J2431568Certificate of AnalysisSep 13, 2024 Z614982
J2431569Certificate of AnalysisSep 13, 2024 Z614982
J2431570Certificate of AnalysisSep 13, 2024 Z614982

Show more⌵

Related Documents

References

1. Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V et al..  (2015)  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases..  Sci Rep,  (13): (11827).  [PMID:26168713] [10.1021/op500134e]
2. Bradford PA, Miller AA, O'Donnell J, Mueller JP.  (2020)  Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates..  ACS Infect Dis,  (6): (1332-1345).  [PMID:32329999] [10.1021/op500134e]
3. Luckey A, Alirol E, Delhomme S, O'Donnell J, Bettiol E, Mueller J, O'Brien S, Gillon JY.  (2023)  Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects..  Clin Transl Sci,  71  (13): (1755-70).  [PMID:36824016] [10.1021/op500134e]

Solution Calculators